204 related articles for article (PubMed ID: 35734391)
1. Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response.
Thompson KJ; Leon-Ferre RA; Sinnwell JP; Zahrieh DM; Suman VJ; Metzger FO; Asad S; Stover DG; Carey L; Sikov WM; Ingle JN; Liu MC; Carter JM; Klee EW; Weinshilboum RM; Boughey JC; Wang L; Couch FJ; Goetz MP; Kalari KR
NAR Cancer; 2022 Jun; 4(2):zcac018. PubMed ID: 35734391
[TBL] [Abstract][Full Text] [Related]
2. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
[TBL] [Abstract][Full Text] [Related]
3. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
4. Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features.
Vtorushin S; Dulesova A; Krakhmal N
J Zhejiang Univ Sci B; 2022 Aug; 23(8):617-624. PubMed ID: 35953756
[TBL] [Abstract][Full Text] [Related]
5. Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping.
Hartung C; Porsch M; Stückrath K; Kaufhold S; Staege MS; Hanf V; Lantzsch T; Uleer C; Peschel S; John J; Pöhler M; Weigert E; Buchmann J; Bürrig KF; Schüler K; Bethmann D; Große I; Kantelhardt EJ; Thomssen C; Vetter M
Breast Care (Basel); 2021 Dec; 16(6):637-647. PubMed ID: 35082572
[TBL] [Abstract][Full Text] [Related]
6. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
Gao ZH; Li CX; Liu M; Jiang JY
BMC Cancer; 2020 Nov; 20(1):1150. PubMed ID: 33238978
[TBL] [Abstract][Full Text] [Related]
7. Targeting triple-negative breast cancer: A clinical perspective.
Popovic LS; Matovina-Brko G; Popovic M; Punie K; Cvetanovic A; Lambertini M
Oncol Res; 2023; 31(3):221-238. PubMed ID: 37305385
[TBL] [Abstract][Full Text] [Related]
8. A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes.
Yoo TK; Kang J; Lee A; Chae BJ
Breast Cancer Res Treat; 2022 Feb; 191(3):599-610. PubMed ID: 35018542
[TBL] [Abstract][Full Text] [Related]
9. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
10. Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype.
Harano K; Wang Y; Lim B; Seitz RS; Morris SW; Bailey DB; Hout DR; Skelton RL; Ring BZ; Masuda H; Rao AUK; Laere SV; Bertucci F; Woodward WA; Reuben JM; Krishnamurthy S; Ueno NT
PLoS One; 2018; 13(10):e0204513. PubMed ID: 30312311
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor expression and outcome of neoadjuvant chemotherapy in triple-negative breast cancer.
Di Leone A; Fragomeni SM; Scardina L; Ionta L; Mulè A; Magno S; Terribile D; Masetti R; Franceschini G
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(4):1910-1915. PubMed ID: 33660830
[TBL] [Abstract][Full Text] [Related]
12. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
[TBL] [Abstract][Full Text] [Related]
13. Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers.
Limsakul P; Choochuen P; Charupanit G; Charupanit K
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672350
[TBL] [Abstract][Full Text] [Related]
14. Triple Negative Breast Cancer: Molecular Subtype-Specific Immune Landscapes with Therapeutic Implications.
Syrnioti A; Petousis S; Newman LA; Margioula-Siarkou C; Papamitsou T; Dinas K; Koletsa T
Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893213
[TBL] [Abstract][Full Text] [Related]
15. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.
Masuda H; Baggerly KA; Wang Y; Zhang Y; Gonzalez-Angulo AM; Meric-Bernstam F; Valero V; Lehmann BD; Pietenpol JA; Hortobagyi GN; Symmans WF; Ueno NT
Clin Cancer Res; 2013 Oct; 19(19):5533-40. PubMed ID: 23948975
[TBL] [Abstract][Full Text] [Related]
16. Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer.
Khadela A; Chavda VP; Soni S; Megha K; Pandya AJ; Vora L
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612226
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women.
Tseng LM; Chiu JH; Liu CY; Tsai YF; Wang YL; Yang CW; Shyr YM
Breast Cancer Res Treat; 2017 Jun; 163(2):241-254. PubMed ID: 28299476
[TBL] [Abstract][Full Text] [Related]
18. Imaging features of triple-negative breast cancers according to androgen receptor status.
Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT
Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169
[TBL] [Abstract][Full Text] [Related]
19. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.
Barton VN; D'Amato NC; Gordon MA; Lind HT; Spoelstra NS; Babbs BL; Heinz RE; Elias A; Jedlicka P; Jacobsen BM; Richer JK
Mol Cancer Ther; 2015 Mar; 14(3):769-78. PubMed ID: 25713333
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype.
Gerratana L; Basile D; Buono G; De Placido S; Giuliano M; Minichillo S; Coinu A; Martorana F; De Santo I; Del Mastro L; De Laurentiis M; Puglisi F; Arpino G
Cancer Treat Rev; 2018 Jul; 68():102-110. PubMed ID: 29940524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]